Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2024-03-05 Earnings Release
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is a press release from MaaT Pharma announcing a clinical trial milestone (completion of patient recruitment for the Phase 2a PICASSO trial) and providing timelines for topline results and publication submission. This type of announcement, which details operational progress, clinical updates, and future reporting schedules, is characteristic of an Earnings Release (ER) or a general operational update. Since it is not a full financial report (10-K, IR), a formal transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification for a timely, high-level operational/clinical update that often accompanies or precedes formal earnings is 'Earnings Release' (ER). It is a direct communication of key operational news to investors. Q4 2024
2024-03-05 English
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated February 29th, 2024, announcing positive safety data review and DSMB recommendation for a clinical trial (MaaT033 in ALS). This type of announcement, detailing clinical trial progress, safety updates, and future data readouts, is characteristic of communications from clinical-stage biotechnology companies to the market. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it is a specific announcement about clinical progress and safety, it does not fit the definitions for AGM-R, MANG, CT, CAP, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. The most appropriate general category for specific, non-financial, non-governance corporate updates that don't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for press releases detailing operational or clinical milestones.
2024-02-29 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 95% confidence The document is a press release from MaaT Pharma, dated February 29, 2024, announcing positive safety evaluation results from the DSMB for their ongoing Phase 1 trial (IASO) evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS). This type of announcement, detailing clinical trial progress, safety data review, and upcoming data expectations, is characteristic of an Earnings Release (ER) or a general press release related to operational/clinical updates. Since it focuses on the initial release of key clinical trial results and safety milestones, it aligns best with the 'Earnings Release' definition, which often covers key operational highlights outside of formal quarterly financial reports. It is not a full financial report (10-K or IR), a transcript (CT), or a management discussion (MDA). Given the context of clinical trial updates being released to the market, ER is the most appropriate fit among the provided options for a significant, periodic operational update. FY 2024
2024-02-29 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital" and explicitly references regulatory articles from the AMF (Autorité des Marchés Financiers) regarding voting rights and share capital disclosure. It provides a specific date (January 31, 2024) for the calculation of shares and voting rights. This type of mandatory periodic disclosure detailing the total number of shares and voting rights aligns directly with the definition of a Declaration of Voting Results & Voting Rights Announcement, although the specific content focuses on the total rights rather than the results of a specific vote. However, among the provided codes, 'DVA' (Declaration of Voting Results & Voting Rights Announcements) is the most appropriate fit for mandatory disclosures concerning the total number of voting rights, as it covers announcements related to voting rights structure. It is not an AGM presentation, an earnings release, or a standard financial report (10-K/IR).
2024-02-08 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital) and explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator). It provides a table detailing the total number of shares and voting rights as of January 31, 2024. This type of regular disclosure concerning the share capital structure and voting rights is a specific regulatory requirement, often related to major shareholding notifications or capital structure updates, but the core content is the monthly count of shares/votes. Among the provided codes, 'MRQ' (Major Shareholding Notification) is the closest fit for notifications regarding changes in share capital structure or significant ownership thresholds, although this specific filing is a mandatory monthly update on the total share count. Given the options, this is a mandatory regulatory disclosure concerning share capital, which aligns best with the scope of 'MRQ' (Major Shareholding Notification) or potentially 'SHA' (Share Issue/Capital Change), but since it's a recurring report on the total count, and not necessarily an announcement of a new issue, 'MRQ' is often used for these periodic capital structure disclosures in European contexts, or 'RNS' as a general regulatory filing. However, since it specifically details the total number of shares and voting rights, which is a key component of major shareholding rules, MRQ is a strong candidate. If a more specific code for 'Total Voting Rights' existed, it would be preferred. Given the options, and recognizing this as a mandatory disclosure related to capital structure/ownership reporting, I will classify it as MRQ, as it directly impacts the calculation of major shareholdings, or RNS if MRQ is too specific. Since the content is a direct, periodic report on the capital structure required by regulation, and not just an announcement of a report, I will lean towards the most relevant structural category. In many databases, these monthly voting rights reports are grouped under capital structure changes or major holdings. I will select MRQ as the most specific fit related to share ownership reporting, although RNS is a safe fallback. Given the highly specific nature of the other codes, MRQ seems intended for share ownership reporting.
2024-02-08 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is titled "MaaT Pharma : Bilan semestriel du contrat de liquidité contracté avec la société de bourse Kepler Cheuvreux" (Semi-annual report of the liquidity contract entered into with the brokerage firm Kepler Cheuvreux). It details the holdings (shares and cash) and transaction volumes (buys and sells) related to a liquidity contract as of December 31, 2023, comparing it to the previous period (June 30, 2023). This type of filing reports on the execution of a share repurchase/trading program managed by a third party, which falls under the category of transactions in the company's own shares or related financing activities. Since the core content is the activity of buying and selling shares (even if managed for liquidity purposes), it aligns best with 'Transaction in Own Shares' (POS). It is not a general financing update (CAP) as it is specific to share trading mechanics, nor is it a Director's Dealing (DIRS) as it concerns the company's own shares via a broker, not insider trades. Given the explicit focus on share transactions under a liquidity contract, POS is the most precise fit.
2024-01-22 French

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.